Personalized support services for patients & providers

Coverage for Repatha® has increased

91%

of Adults Have Coverage for Repatha® in the US1,*

~37,500

patients have received Repatha®2,†

Image of US consisting of Reptha® patients

Additional criteria may apply. Please check with your payor regarding final coverage. The information provided is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Employer policies and the individual patient policies may vary. For the most up-to-date and complete information regarding the status of Repatha®, please contact the managed care plan directly.

Download Access Flashcard

Insurance Verification and Prior Authorization Assistance
  • Insurance counselors can help verify your patients' insurance benefits and determine coverage for Repatha®

  • Our RepathaReady® counselors can help you initiate the insurance verification process. To get started, submit a completed Insurance Verification Form (IVF) to RepathaReady® and fax it to 1-855-REPATHA (737-2842)

Complete the RepathaReady® Intake Form

Download the ICD-10 Guide

Repatha® Fulfillment
  • Once coverage has been determined for plans that allow prescriptions to be filled by specialty pharmacy, RepathaReady® can send the prescription to the specialty pharmacy for mail delivery to your patient

Comprehensive Coverage Support
  • Occasionally, you may need additional insurance support, such as assistance with formulary exceptions and appeals

  • Our counselors can initiate appeals/exceptions, track coverage status, and provide sample letters to payors for your use

  • We can help determine eligibility for alternative coverage and inform patients of options

In Office One-on-One Support
  • Repatha® Access Specialists can visit your office to help you with prior authorizations and other insurance and financial assistance questions

  • RepathaReady® Nurses can come to your office or to your patient's home to provide injection training

*Repatha® is on the formulary of the plans of 91% of adults with prescription drug coverage. Based on reported coverage as of March 2017. Source: Managed Markets Insights & Technology.

Based on IMS (NBRx) data for the period of September 11, 2015 to March 31, 2017. These data include only dispensed scripts.

Repatha® copay card

Repatha® Copay Card*

Pay no more than $5

  • No income eligibility requirements

  • Reduces out of pocket (OOP) costs for Repatha®, including co-payments, co-insurance, and prescription deductibles

  • Pays up to an annual maximum of $5,500

  • Must be reactivated every 12 months

  • Activate a Repatha® Copay Card at www.repatha.com/copaycard or by calling 1‑844‑REPATHA (1‑844‑737‑2842)
    Hours: 9am‑11pm ET, Monday‑Friday

*Eligibility Criteria—Open to patients with a Repatha® prescription who have commercial insurance. Patients may not seek reimbursement for value received from the Repatha® Copay Card from any third-party payors, including a flexible spending account or healthcare savings account. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE® or where prohibited by law. If at any time patients begin receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patients will no longer be able to use this card and you must call 1-844-REPATHA to stop participation. Restrictions may appy. Offer subject to change or discontinuation without notice.

Financial assistance options are available for different patient types

Commercial Insurance

Repatha® Copay Card

Eligible patients

pay no more than

$5*

for each Repatha® prescription
regardless of income

Please see program details and eligibility criteria below. Applies to deductible, co-insurance, and/or copay for Repatha®.

Medicare Part D

Referrals to Independent
Copay Foundations

Eligible patients may

receive assistance
to help them
afford the cost of
their medicine

Provided through third-party foundations (501(c)(3), tax-exempt nonprofit organizations. Amgen has no control over independent, third-party programs and provides referrals as a courtesy only.

Uninsured or underinsured

Referrals to
The Amgen Safety Net Foundation

Eligible patients

receive Repatha®
at no cost

For more information on eligibility criteria, see AmgenSafetyNetFoundation.com

For more information, contact RepathaReady® at 1-8‌4‌4-R‌E‌PA‌T‌HA (1-8‌4‌4-7‌37-2‌8‌4‌2)

*Please see program details and eligibility criteria below. Applies to deductible, co-insurance, and/or copay for Repatha®.

Provided through third-party foundations (501(c)(3), tax-exempt nonprofit organizations. Amgen has no control over independent, third-party programs and provides referrals as a courtesy only.

*Eligibility Criteria—Open to patients with a Repatha® prescription who have commercial insurance. Patients may not seek reimbursement for value received from the Repatha® Copay Card from any third-party payors, including a flexible spending account or healthcare savings account. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE® or where prohibited by law. If at any time patients begin receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patients will no longer be able to use this card and you must call 1-844-REPATHA to stop participation. Restrictions may appy. Offer subject to change or discontinuation without notice.

Call 1-8‌4‌4-‌R‌EPA‌T‌HA (‌8‌44‌-7‌3‌7-2‌8‌4‌2) from 9am-11pm ET, Monday-Friday and our live counselors can help your office and your patients.

RepathaReady® Online is a resource now available to help optimize the process for accessing Repatha®.
You and your office can:

  1. Submit insurance verification and related documents online

  2. Receive summary of benefits and other updates electronically

  3. Manage all documents and see all patients in one online location

Register Now

SEE NEXT

References:

  1. Data on file, Amgen [1]; 2016.

  2. Data on file, Amgen [2]; 2016.

IMPORTANT SAFETY INFORMATION

See More

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®.

Allergic reactions: Hypersensitivity reactions (e.g. rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse reactions: The most common adverse reactions (> 5% of Repatha®-treated patients and more common than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

In a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% of Repatha®-treated patients and 1% of placebo-treated patients. The most common adverse reaction that led to Repatha® treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for Repatha® and placebo, respectively).

Adverse reactions from a pool of the 52-week trial and seven 12-week trials:
Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in Repatha®-treated patients and placebo-treated patients were 0.1% and 0%, respectively.

Allergic reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Neurocognitive events were reported in less than or equal to 0.2% in Repatha®-treated and placebo-treated patients.

In a pool of placebo- and active-controlled trials, as well as open-label extension studies that followed them, a total of 1,988 patients treated with Repatha® had at least one LDL‑C value < 25 mg/dL. Changes to background lipid-altering therapy were not made in response to low LDL-C values, and Repatha® dosing was not modified or interrupted on this basis. Although adverse consequences of very low LDL-C were not identified in these trials, the long-term effects of very low levels of LDL-C induced by Repatha® are unknown.

Musculoskeletal adverse reactions were reported in 14.3% of Repatha®-treated patients and 12.8% of placebo-treated patients. The most common adverse reactions that occurred at a rate greater than placebo were back pain (3.2% versus 2.9% for Repatha® and placebo, respectively), arthralgia (2.3% versus 2.2%), and myalgia (2.0% versus 1.8%).

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with Repatha®.

INDICATION
Repatha® is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD), who require additional lowering of low density lipoprotein cholesterol (LDL-C).

The effect of Repatha® on cardiovascular morbidity and mortality has not been determined.

Please see full Prescribing Information.

Back to Top